Patritumab deruxtecan · HERTHENA-Breast04
Merck lists this exact HERTHENA-Breast04 study. Its dual PFS/OS design is distinct from lung-cancer trials or prior ADC results. patritumab deruxtecan — phase 3 study in Breast Neoplasms. NCT07060807 lists Progression Free Survival (PFS) as a primary outcome (Up to approximately 45 months). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2033-07-14 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
- The registry lists 2 primary outcome measures. A market must explicitly specify which endpoint or conjunction resolves YES; this card highlights one measure only.
Primary evidence
Phase 3 breast-cancer monitor — date unconfirmed
Potential outcome market
Will patritumab deruxtecan meet the prespecified primary endpoint in NCT07060807 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.